| Identifying Factors Influencing In-Hospital Relapse in Pemphigus Patients (NCT06167408) | First Affiliated Hospital of Chongqing Medical University | 2022-01-01 |
| COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders (NCT05000216) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-08-13 |
| A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus) (NCT04598477) | argenx | 2021-07-15 |
| Comparative Analysis of the Th17 Cellular Response in Active and Inactive Pemphigus Vulgaris Patients (NCT04096222) | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | 2021-06-29 |
| Comparing DCP and DAP for Pemphigus Vulgaris (NCT06846255) | Jinnah Postgraduate Medical Centre | 2021-06-15 |
| A Study to Evaluate Efficacy and Safety of Abatacept in Participants of Pemphigus Vulgaris (PV) (NCT05303272) | Tongji Hospital | 2021-02-01 |
| Dexamethasone Solution and Dexamethasone in Mucolox™ (NCT04540133) | University of California, San Francisco | 2020-12-26 |
| A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus) (NCT04598451) | argenx | 2020-12-01 |
| A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV) (NCT04422912) | Cabaletta Bio | 2020-09-29 |
| Efficacy of Interleukin-2 Gargle in the Treatment of Oral Mucosa Lesion in Pemphigus Vulgaris (NCT04023149) | Second Xiangya Hospital of Central South University | 2020-04-02 |
| Phenotypic and Functional Characterisation of Human B-cell Response in Pemphigus (NCT04117529) | Assistance Publique - Hôpitaux de Paris | 2019-10-22 |
| A Study of the Safety and Tolerability of INCB050465 in Pemphigus Vulgaris (NCT03780166) | Incyte Corporation | 2019-03-01 |
| A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus (NCT03334058) | argenx | 2017-10-18 |
| Polyclonal Regulatory T Cells (PolyTregs) for Pemphigus (NCT03239470) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-10-10 |
| A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus) (NCT03075904) | Alexion Pharmaceuticals, Inc. | 2017-07-18 |
| Serum IL-21 Levels in Patients With Pemphigus Vulgaris (NCT03177213) | Assiut University | 2017-06-01 |
| Autoimmune Blistering Diseases Study (NCT02753777) | University of Pennsylvania | 2016-04-01 |
| A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris (NCT02704429) | Principia Biopharma, a Sanofi Company | 2016-01-22 |
| A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV) (NCT02383589) | Hoffmann-La Roche | 2015-05-26 |
| Study of Efficacy and Safety of VAY736 in Patients With Pemphigus Vulgaris (NCT01930175) | Novartis Pharmaceuticals | 2013-12-18 |
| Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris (NCT01920477) | Novartis Pharmaceuticals | 2013-08-13 |
| Azathioprine Versus Placebo in Pemphigus Vulgaris Treated With Prednisolone (NCT00626678) | Tehran University of Medical Sciences | 2008-01-01 |
| Use of KC706 for the Treatment of Pemphigus Vulgaris (NCT00606749) | Kemia, Inc | 2007-11-01 |
| Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus (NCT00483119) | NYU Langone Health | 2007-04-01 |
| Study of Etanercept (Enbrel) in the Treatment of Pemphigus Vulgaris (NCT00135720) | Massachusetts General Hospital | 2004-06-01 |
| Safety Study of PI-0824 to Treat Pemphigus Vulgaris (NCT00063752) | Peptimmune | 2003-07-01 |
| Efficacy of Dapsone as a Steroid Sparing Agent in Pemphigus Vulgaris (NCT00429533) | Jacobus Pharmaceutical | 1996-11-01 |